1-(2-methoxy-2-oxoethyl)cyclopropane-1-carboxylic acid | 1889271-18-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-(2-methoxy-2-oxoethyl)cyclopropane-1-carboxylic acid
• CAS: 1889271-18-4
• 化学式: C₇H₁₀O₄
• 分子量: 158.154
• InChiKey: SJKISQXOKNLZKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them
  申请人：Goldstein Solo

  公开号：US20100317698A1

  公开（公告）日：2010-12-16

  Compounds of formula (I): wherein: n represents an integer of from 1 to 6 inclusive, X represents an oxygen atom or an NR 6 group, Y represents a carbon atom or a nitrogen atom, Z represents a carbon atom or a nitrogen atom, R 1 and R 2 represent a hydrogen atom or an alkyl or arylalkyl group, R 3 and R 4 represent a hydrogen atom or an alkyl group, R 5 represents a hydrogen atom or an alkyl, halogen, hydroxy, alkoxy, cyano, nitro, acyl, alkoxycarbonyl, trihaloalkyl, trihaloalkoxy or optionally substituted amino group, R 6 represents a hydrogen atom or an alkyl or arylalkyl group, Ra, Rb, Rc, Rd and Re are as defined in the description. Medicinal products containing the same which are useful as specific nicotinic ligands of α4β2 receptors.

  式（I）的化合物中：其中：n代表1至6之间的整数，X代表氧原子或NR6基团，Y代表碳原子或氮原子，Z代表碳原子或氮原子，R1和R2代表氢原子或烷基或芳基烷基，R3和R4代表氢原子或烷基，R5代表氢原子或烷基、卤素、羟基、烷氧基、氰基、硝基、酰基、烷氧羰基、三卤代烷基、三卤代烷氧基或可选取代氨基，R6代表氢原子或烷基或芳基烷基，Ra、Rb、Rc、Rd和Re如描述中所定义。含有这些化合物的药物制剂，可用作α4β2受体的特异性烟碱酸配体。
• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20160311778A1

  公开（公告）日：2016-10-27

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和方法，用于治疗丙型肝炎病毒（HCV）感染。还公开了含有这些化合物的制药组合物和使用这些化合物治疗HCV感染的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170320833A1

  公开（公告）日：2017-11-09

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和方法，用于治疗丙型肝炎病毒（HCV）感染。还公开了含有这些化合物的制药组合物和使用这些化合物治疗HCV感染的方法。
• HEPATITIS C VIRUS INHIBITOR
  申请人：Bristol-Myers Squibb Company

  公开号：US20170355689A1

  公开（公告）日：2017-12-14

  The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
• US8143414B2
  申请人：——

  公开号：US8143414B2

  公开（公告）日：2012-03-27